Prescribed Drug Spending in Canada, 2012: A Focus on Public Drug Programs

Size: px
Start display at page:

Download "Prescribed Drug Spending in Canada, 2012: A Focus on Public Drug Programs"

Transcription

1 Prescribed Drug Spending in Canada, 2012: A Focus on Public Drug Programs Spending and Health Workforce

2 Our Vision Better data. Better decisions. Healthier Canadians. Our Mandate To lead the development and maintenance of comprehensive and integrated health information that enables sound policy and effective health system management that improve health and health care. Our Values Respect, Integrity, Collaboration, Excellence, Innovation

3 Table of Contents Acknowledgements... iii About CIHI... v Executive Summary... vii Highlights... ix Introduction... 1 Prescribed Drug Spending in Canada... 3 How Much Do Canadians Spend on Prescribed Drugs?... 3 What Are the Trends in Prescribed Drug Spending in Canada?... 5 What Proportion of Prescribed Drug Spending Is Funded by the Public Sector?... 7 Public Drug Program Spending in Selected Jurisdictions... 8 Which Drugs Account for the Highest Proportion of Public Drug Program Spending?... 9 Spending by Broad Therapeutic Category... 9 Spending by Drug Class How Is Public Drug Program Spending Distributed? Which Drugs Contributed to the Observed Trends in Public Drug Program Spending? Appendix A: Glossary of Terms Appendix B: Overview of Drug Program Design and Formulary Appendix C: Drug Classification Systems Appendix D: Factors That May Influence Drug Use and Expenditure in Canada Appendix E: Methodological Notes Appendix F: Provincial and Territorial Drug Programs Appendix G: Percentage of Total Public Drug Program Spending, by Broad Therapeutic Category, Selected Jurisdictions,* Appendix H: Percentage of Paid Beneficiaries and Total Drug Program Spending, by Program Spending per Paid Beneficiary, Selected Jurisdictions,* 2007 and Appendix I: Top 10 Drug Classes With the Highest Proportion of Total Program Spending, by Jurisdiction, References... 47

4

5 Acknowledgements The Canadian Institute for Health Information (CIHI) wishes to acknowledge and thank the following groups for their contributions to Prescribed Drug Spending in Canada, 2012: A Focus on Public Drug Programs: Prince Edward Island Provincial Pharmacare Program, Department of Health and Wellness Nova Scotia Pharmaceutical Services, Department of Health and Wellness New Brunswick Pharmaceutical Services Branch, Department of Health Ontario Pharmaceutical Services Coordination Unit, Ministry of Health and Long-Term Care Manitoba Provincial Drug Programs, Department of Health Saskatchewan Drug Plan and Extended Benefits Branch, Ministry of Health Alberta Pharmaceutical Funding and Guidance Branch, Ministry of Health British Columbia Health Outcomes and Economic Analysis Division, Ministry of Health First Nations and Inuit Health Branch, Non-Insured Health Benefits Directorate, Health Canada Please note that the analyses and conclusions in this document do not necessarily reflect those of the organizations mentioned above. iii

6

7 About CIHI The Canadian Institute for Health Information (CIHI) collects and analyzes information on health and health care in Canada and makes it publicly available. Canada s federal, provincial and territorial governments created CIHI as a not-for-profit, independent organization dedicated to forging a common approach to Canadian health information. CIHI s goal: to provide timely, accurate and comparable information. CIHI s data and reports inform health policies, support the effective delivery of health services and raise awareness among Canadians of the factors that contribute to good health. Production of this analysis is made possible by financial contributions from Health Canada and provincial and territorial governments. The views expressed herein do not necessarily represent the views of Health Canada or any provincial or territorial government. v

8

9 Executive Summary This report focuses on prescribed drug expenditure, the third-largest major category of total health spending in Canada. The first section of this report provides an overview of prescribed drug spending in Canada using data from a Canadian Institute for Health Information (CIHI) database, the National Health Expenditure Database (NHEX), which contains a historical series of macro-level drug expenditure statistics by province and territory. The second section of this report provides a more in-depth look at public drug program spending using drug claims data submitted to CIHI s National Prescription Drug Utilization Information System (NPDUIS) Database, which contains claims from public drug programs in eight provinces Prince Edward Island, Nova Scotia, New Brunswick, Ontario, Manitoba, Saskatchewan, Alberta and British Columbia as well as one federal program administered by the First Nations and Inuit Health Branch (FNIHB). How much do Canadians spend on prescribed drugs? In 2013, Canadians spent an estimated $34.5 billion on drugs, the majority of which (85.0%) was spent on prescribed drugs, at an estimated $29.3 billion. Prescribed drugs accounted for an estimated 13.9% of total health expenditure. What are the trends in prescribed drug spending in Canada? In 2013, the annual rate of change in prescribed drug spending (2.3%) was at its secondlowest point in more than two decades. Public-sector drug spending in Canada is forecast to have grown only negligibly, at a rate of less than 0.1% the lowest rate since 1996, when spending decreased. Between 2001 and 2013, drugs were one of the fastest-growing major categories of health system spending. However, since 2005, drug spending has grown more slowly than hospital and physician spending. What proportion of prescribed drug spending is funded by the public sector? In 2013, an estimated 41.6% of prescribed drug spending was financed by the public sector, with the remainder financed by private insurers (34.5%) and out of pocket by households and individuals (23.9%). The proportion of prescribed drugs financed by the public sector varied across provinces, ranging from 29.3% in New Brunswick to 47.6% in Saskatchewan. Which drugs account for the highest proportion of public drug program spending? In 2012, the top 10 drug classes, in terms of public drug program spending, accounted for 34.2% of spending in the nine jurisdictions. Six of the top 10 drug classes were used to treat conditions related to the cardiovascular and nervous systems. Tumor necrosis factor alpha inhibitors (anti-tnf drugs), which are used to treat conditions such as rheumatoid arthritis and Crohn s disease, accounted for the highest proportion of public drug program spending in 2012; these were followed by statins, used to lower cholesterol levels, and proton pump inhibitors, used to treat gastroesophageal reflux disease. vii

10 How is public drug program spending distributed? In 2012, more than half of public drug spending (60.8%) was for a relatively small proportion of individuals (12.7%) for whom public drug programs paid $2,500 or more toward their annual drug costs. A total of 6.2% of drug program spending was for more than half of individuals (52.1%) for whom drug programs paid less than $500 toward their annual drug costs. The distribution of drug program spending was similar among the nine jurisdictions. Which drugs contributed to the observed trends in public drug program spending? Between 2002 and 2012, drug program spending grew at an average annual rate of 6.3%; however, growth from 2007 to 2012 (3.5%) was much slower than growth from 2002 to 2007 (9.2%). Anti-TNF drugs and antineovascularization agents, used to treat age-related macular degeneration, were the top two drug classes that contributed most to the growth of public drug spending between 2007 and 2012, accounting for 54.8% and 12.6% of growth, respectively. Four of the top 10 drug classes that accounted for the highest proportions of total program spending in 2012 experienced a decline in spending between 2007 and In each of these four classes, patents on commonly used drugs expired, allowing for the entry of lower-priced generic versions. In 2012, generic products accounted for 38.8% of public drug program spending and 72.4% of accepted claims. In cases where only generic products were available, generics accounted for 65.5% of spending and 80.6% of claims in viii

11 Highlights This report focuses on prescribed drug expenditure, the third-largest major category of health spending in Canada. The first section provides an overview of prescribed drug spending using CIHI s NHEX data. The second section looks more in-depth at public drug program spending using data from CIHI s NPDUIS Database. Prescribed drug spending is forecast to have grown by 2.3% in 2013, its second-lowest rate in more than two decades. Prescribed drug spending is expected to have reached $29.3 billion, accounting for 85.0% of total drug spending ($34.5 billion). Growth in prescribed drug spending has slowed since the early 2000s, reaching its lowest rate of 1.3% in Since 2005, prescribed drug spending has grown more slowly than hospital and physician spending. Public-sector spending on prescribed drugs in 2013, which represents 41.6% of total prescribed drug spending, is forecast to have been $12.2 billion, the same as for The introduction of lower-cost generic drugs in several high-use drug classes (for example, cholesterol-lowering agents and proton pump inhibitors) and the implementation of generic pricing policies contributed to the slowed growth in public-sector spending on prescribed drugs. Generic drugs grew as a share of public-sector spending and as a share of the number of accepted claims. Generic drugs accounted for 38.8% of public drug program spending and 72.4% of claims. Among cases where only generic products were available, generics accounted for 65.5% of spending and 80.6% of claims. Ten drug classes accounted for more than a third (34.2%) of public drug program spending in Six of the top 10 drug classes were used to treat conditions related to the cardiovascular and nervous systems. Anti-TNF drugs, biologic drugs used to treat rheumatoid arthritis and Crohn s disease, accounted for the highest proportion of spending in These drugs are used by a relatively small number of beneficiaries and have a significantly higher average cost. High-cost beneficiaries (for whom public drug programs paid $2,500 or more toward drug costs) accounted for 12.7% of all beneficiaries and 60.8% of public drug spending. ix

12

13 Introduction Spending on prescribed drugs continues to rise, but recently, growth has occurred at a much slower rate. It is forecast to have reached almost $29.3 billion in 2013, representing an annual growth of 2.3% from the previous year, the second-lowest annual growth rate in the past 20 years (in 2011, drug spending increased at just 1.3%). 1 Multiple payers are involved in the financing of prescribed drugs, including public drug programs, private insurers and households. In 2013, public-sector expenditure on prescribed drugs is expected to have reached $12.2 billion, which is the same as it was in 2012, accounting for 41.6% of prescribed drug spending in Canada. To support public drug program management and decision-making, there is an ongoing need for detailed information about drug use and expenditure. This report focuses on prescribed drug expenditure, one of the largest major categories of total health spending in Canada. The first section of this report provides an overview of prescribed drug spending in Canada using data from a Canadian Institute for Health (CIHI) database, the National Health Expenditure Database (NHEX), which contains a historical series of macro-level drug expenditure statistics by province and territory. It examines trends in overall prescribed drug spending in Canada, as well as spending by age group and by source of funds. It also compares these trends with those observed in other major sectors of publicly funded health care spending in Canada. The second section of this report provides a more in-depth look at public drug program spending using drug claims data submitted to CIHI s National Prescription Drug Utilization Information System (NPDUIS) Database. It looks at the types of drugs and characteristics of people accounting for the majority of drug spending and examines some of the components of drug spending that contributed to the observed trends over the past 10 years. The NPDUIS Database contains claims from public drug programs in eight provinces Prince Edward Island, Nova Scotia, New Brunswick, Ontario, Manitoba, Saskatchewan, Alberta and British Columbia as well as one federal program administered by the First Nations and Inuit Health Branch (FNIHB). 1

14

15 Prescribed Drug Spending in Canada This section examines prescribed drug spending in Canada and will address the following questions: How much do Canadians spend on prescribed drugs? What are the trends in prescribed drug spending in Canada? What proportion of prescribed drug spending is funded by the public sector? A glossary (Appendix A) provides definitions of key terms used in this report. How Much Do Canadians Spend on Prescribed Drugs? Canadians spent an estimated $34.5 billion on drugs in 2013, the majority of which (85.0%) was spent on prescribed drugs, at an estimated $29.3 billion. Multiple payers are involved in the financing of prescribed drugs. In the public sector, these payers include provincial/territorial and federal drug subsidy programs and social security funds (such as workers compensation boards). In the private sector, payers include private insurers and households or individuals paying out of pocket. In 2013, $12.2 billion, or 41.6% of prescribed drug spending, is expected to have been financed by the public sector (Figure 1). In the private sector, prescribed drug spending financed by private insurers is expected to have been $10.1 billion, with the remaining $7.0 billion financed by Canadian households. Figure 1: Prescribed Drug Expenditure, by Source of Finance, Canada, 2013 f Notes * Social Security Funds (SSFs) include health care spending by workers compensation boards and the premium component of the Quebec Drug Insurance Fund. f: Forecast. $ billions; percentage share of total drug expenditure. Source National Health Expenditure Database, 2013, Canadian Institute for Health Information. 3

16 Spending in 2013 on hospitals, prescribed drugs and physicians, combined, is forecast to have accounted for 58.3% of total health spending in Canada. Among the nine major categories of health spending, prescribed drugs are expected to account for 13.9% of spending, the thirdlargest category after hospitals (29.6%) and physicians (14.8%). The share of prescribed drugs in total health spending varied among provinces, ranging from the lowest in British Columbia (11.1%) and Manitoba (11.2%) to the highest in Quebec (16.8%) and New Brunswick (15.2%). 1 Figure 2: Total Health Expenditure, by Use of Funds, Canada, 2013 f Notes f: Forecast. $ billions; percentage share of total drug expenditure. Source National Health Expenditure Database, 2013, Canadian Institute for Health Information. 4

17 What Are the Trends in Prescribed Drug Spending in Canada? For more than a decade, drugs have been one of the fastest-growing components of health system spending in Canada. Spending on prescribed drugs in Canada grew rapidly in the early 2000s when many blockbuster drug classes expanded in terms of use and cost (Figure 3). Since then, growth in prescribed drug spending has slowed, and in 2011 spending grew at the lowest rate (1.3%) in more than two decades. Although slightly higher than in 2011, growth for 2012 and 2013 is also forecast to be at similarly low rates. It should be noted that the higher growth in 2010 was due to a change in the way out-of-pocket drug spending was measured. i Growth in drug spending by private insurers (3.3%) was much more similar to the growth in public-sector prescribed drug spending for that year (2.1%). Figure 3: Prescribed Drug Spending, Canada, 2001 to 2013 f Note f: Forecast. Source National Health Expenditure Database, 2013, Canadian Institute for Health Information. i. Due to a major redesign of the Survey of Household Spending by Statistics Canada in 2010, private prescription drug estimates from 2009 and earlier years should not be compared with those between 2010 and These were effectively two different surveys before and after the methodology redesign. The differences in survey design are responsible for the spike in private prescribed drug spending observed in For more information, please refer to CIHI s report National Health Expenditure Trends, 1975 to

18 There has been a similar decline in growth for publicly financed drug spending, which is the focus of the remainder of this report. In 2013, public-sector spending on prescribed drugs is forecast to have grown only negligibly, at a rate of less than 0.1% the lowest rate since 1996, when drug spending last declined. Other categories of health spending have also seen a decline in the rate of increase of public-sector spending over the past 10 years; however, the decline in growth rates was more pronounced for drugs. Between 2001 and 2006, public drug spending grew at a more rapid rate relative to that of other components of health care spending an average annual rate of 9.6% (Figure 4). In contrast, between 2006 and 2011, public drug spending, which increased at an average annual rate of 4.5%, grew more slowly than hospital spending (6.3%) and physician spending (7.9%). Slower growth in drug spending continued in 2012 and Figure 4: Average Annual Growth Rate of Public Health Spending, by Selected Categories, 2001 to 2013 f Note f: Forecast. Source National Health Expenditure Database, 2013, Canadian Institute for Health Information. 6

19 What Proportion of Prescribed Drug Spending Is Funded by the Public Sector? In 2013, the public sector is forecast to have financed 41.6% of prescribed drug spending in Canada (Figure 5). The public share of prescribed drug spending varied among provinces, ranging from the lowest in New Brunswick (29.3%) and P.E.I. (33.5%) to the highest in Saskatchewan (47.6%) and Quebec (46.9%). Figure 5: Publicly Funded Drug Spending as a Percentage of Prescribed Drug Spending, by Source of Finance, by Province and Canada, 2013 f Notes * Social Security Funds include health care spending by workers compensation boards and the premium component of the Quebec Drug Insurance Fund. f: Forecast. Source National Health Expenditure Database, 2013, Canadian Institute for Health Information. The majority of public-sector spending in each province is funded by the provincial government; it should be pointed out that the federal share of spending is much higher in Manitoba and Saskatchewan because of the proportionally higher First Nations population in those provinces. FNIHB administers a federal drug plan that provides drug coverage to eligible First Nations populations in all provinces and territories in Canada. Conversely, the federal share is lower in Ontario because the provincial drug program funds costs that are funded federally in other provinces. The share of prescribed drug spending financed by the provincial governments ranges from 25.6% in New Brunswick to 39.8% in Alberta. 7

20 Seniors account for a high proportion of public drug program spending due to the design of these programs (see Appendix B). In 2011, ii seniors accounted for 59.9% of the $10.3 billion in provincial/territorial government expenditure on prescribed drugs (Table 1). Seniors are estimated to account for close to 40% of all retail spending on prescribed drugs. 2 Table 1: Percentage of Provincial/Territorial Government-Funded Drug Spending, by Age Group, Canada, 2011* Provincial/Territorial Government Spending ($ Billions) $10.3 Age Group 19 Non-Seniors 40.1% 2.3% % % Seniors 59.9% 26.2% % % Note * 2011 is the most recent year for which this data is available. Source National Health Expenditure Database, 2013, Canadian Institute for Health Information. Public Drug Program Spending in Selected Jurisdictions To better understand trends in public drug program spending, this section examines public drug program spending using data submitted to the NPDUIS Database by nine federal/provincial public drug programs. This section will address the following questions: Which drugs account for the highest proportion of public drug program spending? How is public drug program spending distributed? What drugs contributed to the observed trends in public drug spending? ii. This is the most recent data year for which data broken down by age group was available in NHEX. 8

21 Which Drugs Account for the Highest Proportion of Public Drug Program Spending? Spending by Broad Therapeutic Category In 2012, total public drug program spending among the nine jurisdictions was almost $7.4 billion. Among 14 broad therapeutic categories, the top two categories nervous system and cardiovascular system drugs accounted for 39.3% of total public drug program spending (Table 2). Spending by broad therapeutic category provides a high-level overview of the types of conditions that account for drug spending. Broad therapeutic categories are regarded as groups of different chemicals that act on the same organ or system (see Appendix C). Table 2: Percentage of Total Public Drug Program Spending, by Broad Therapeutic Category, Selected Jurisdictions,* 2012 Broad Therapeutic Category TPS ($ Millions) Proportion of TPS (%) Nervous System 1, Cardiovascular System 1, Antineoplastic and Immunomodulating Agents 1, Alimentary Tract and Metabolism Respiratory System Anti-Infectives for Systemic Use Sensory Organs Musculoskeletal System Blood and Blood-Forming Organs Genitourinary System and Sex Hormones Systemic Hormonal Preparations Dermatologicals Various Anti-Parasitic Products, Insecticides and Repellents Unassigned Total 7, Notes * The nine jurisdictions submitting claims data to the NPDUIS Database as of December 2013 are Prince Edward Island, Nova Scotia, New Brunswick, Ontario, Manitoba, Saskatchewan, Alberta, British Columbia and the First Nations and Inuit Health Branch. This category includes drug products without an Anatomical Therapeutic Chemical (ATC) Code assigned by Health Canada and products assigned as pseudo Drug Identification Numbers. TPS: Total program spending. Source National Prescription Drug Utilization Information System Database, Canadian Institute for Health Information. 9

22 In general, the distribution of spending across broad therapeutic categories was similar across jurisdictions, with cardiovascular and nervous system drugs each accounting for the highest proportion of spending in four of the nine jurisdictions, and appearing among the top four broad therapeutic categories in each jurisdiction (see Appendix G). In Manitoba, antineoplastic and immunomodulating agents (used in cancer treatment) accounted for the highest proportion of spending, at 26.0%. The higher proportion spent on this category in Manitoba is likely due in part to the fact that the province covers oral cancer drugs through the public drug program. iii However, other jurisdictions that fund oral cancer drugs through the public drug program have much lower shares of spending for these drugs, suggesting that other factors are also influencing the distribution of spending across therapeutic categories. For a more comprehensive list of factors, see Appendix D. It should be noted that public drug program spending does not include spending on drugs dispensed in hospitals or on those funded through cancer agencies and other special programs. Spending on these drugs can impact the distribution of spending across broad therapeutic categories, especially as it relates to antineoplastic and immunomodulating agents. In 2009, an estimated $2.4 billion was spent on drugs dispensed in hospitals, $800 million of which was spent on cancer drugs. 3 The distribution of drug program spending across broad therapeutic categories is also impacted by the drug program design in each jurisdiction, which in turn impacts the age distribution of the active beneficiary population (see Appendix B). For example, FNIHB, Manitoba and B.C. the three jurisdictions where non-seniors account for the highest proportion of drug program spending spend the highest proportion on nervous system drugs (the category accounting for the highest proportion of drug program spending for non-seniors) and the lowest proportion on cardiovascular drugs (the category accounting for the highest proportion of drug program spending seniors). In contrast, Nova Scotia and Alberta the two provinces where seniors account for the highest proportion of drug program spending spend the highest proportion on cardiovascular drugs and the lowest proportion on nervous system drugs. It is important to note, however, that not all jurisdictions follow this pattern. For example, Ontario, where the proportion spent on seniors is third-highest among the nine jurisdictions, spends more on nervous system drugs than on cardiovascular drugs, again highlighting that other factors aside from drug program design are influencing these numbers. Other factors can include formulary coverage, demographics and prescribing patterns. Spending by Drug Class Spending by drug class provides more detail in terms of the specific conditions being treated. Drug classes are regarded as groups of different chemicals that act in the same way to treat similar medical conditions. iii. As of April 2012, the Home Cancer Drug Program provides oral cancer and some supportive drugs to cancer patients in Manitoba. Previously, some of these drugs were covered through Manitoba s Pharmacare Program. For more details on public drug program design, please see the NPDUIS Plan Information document. 10

23 In 2012, among the nine jurisdictions, anti-tnf drugs, which are used to treat conditions such as rheumatoid arthritis and Crohn s disease, accounted for the highest proportion of public drug program spending, at 6.5%. HMG-CoA reductase inhibitors (commonly referred to as statins ), used to lower cholesterol levels, accounted for the second-highest proportion of spending, at 5.6% (Table 3). Table 3: Top 10 Drug Classes by Total Program Spending, Selected Jurisdictions,* 2012 Drug Class Common Uses TPS ($ Millions) Tumor Necrosis Factor Alpha Inhibitors Rheumatoid Arthritis, Crohn s Disease (Anti-TNF Drugs) HMG-CoA Reductase Inhibitors (Statins) High Cholesterol Proton Pump Inhibitors (PPIs) Gastroesophageal Reflux Disease, Peptic Ulcer Disease Proportion of TPS (%) Antineovascularization Agents Age-Related Macular Degeneration Adrenergics and Other Drugs for Asthma, Emphysema, Obstructive Airway Diseases Chronic Bronchitis Natural Opium Alkaloids Management of Moderate to Severe Pain Angiotensin-Converting Enzyme (ACE) Heart Failure, High Blood Pressure Inhibitors, Plain Selective Serotonin Reuptake Inhibitors Depression Diazepines, Oxazepines, Thiazepines Schizophrenia, Bipolar Disorder and Oxepines Other Antidepressants Depression Combined Top 10 2, Notes * The nine jurisdictions submitting claims data to the NPDUIS Database as of December 2013 are Prince Edward Island, Nova Scotia, New Brunswick, Ontario, Manitoba, Saskatchewan, Alberta, British Columbia and the First Nations and Inuit Health Branch. TPS: Total program spending. Source National Prescription Drug Utilization Information System Database, Canadian Institute for Health Information. As expected, based on the distribution of spending by broad therapeutic category, two of the top 10 drug classes in terms of drug program spending act on the cardiovascular system, and four act on the nervous system (Table 3). These top 10 drug classes accounted for 34.2% of drug program spending in A comparison of drug spending by jurisdictions in 2012 reveals that the top 3 drug classes among the nine jurisdictions combined (anti-tnf agents, statins and proton pump inhibitors, or PPIs) accounted for the highest proportion of spending in six of the nine jurisdictions and appear among the top 10 drug classes in each jurisdiction (Appendix I). However, there are some jurisdictional differences in the distribution of spending across drug classes. Most notably, the proportion of spending on anti-tnf agents varied from 3.5% for FNIHB to 14.1% in Manitoba. 11

24 There was also variation in the proportion of spending on statins across provinces, from 3.5% in Manitoba to 8.0% in Nova Scotia and P.E.I. This was due in large part to differences in the age distribution across provinces and the fact that statins are most commonly used among seniors. The jurisdictions with the lowest proportion of spending on statins were the three jurisdictions without designated seniors programs. In Alberta and Ontario, antineovascularization agents account for a significant portion of spending (6.1% and 4.3%, respectively). Almost all of this spending (99.9%) is for the drug ranibizumab (sold under the brand name Lucentis), commonly used to treat age-related macular degeneration, which is a condition that results in the loss of vision. In other provinces, the majority of public spending on ranibizumab is through special programs and is not included in NPDUIS drug claims data. Again, it should be noted that many factors in addition to drug program design can influence spending (see Appendix D). Given the fact that seniors account for close to two-thirds of public drug program spending, iv it is not surprising that seven of the top 10 drug classes also appeared on the top 10 list for seniors in 2012 (Table 4). In this same year, three cardiovascular-related drug classes were on the seniors top 10 list, and these drug classes made up 14.8% of public drug spending for seniors. Table 4: Top 10 Drug Classes by Total Program Spending on Seniors, Selected Jurisdictions,* 2012 Drug Class Common Uses TPS ($ Millions) HMG-CoA Reductase Inhibitors (Statins) High Cholesterol Antineovascularization Agents Age-Related Macular Degeneration Proton Pump Inhibitors (PPIs) Angiotensin-Converting Enzyme (ACE) Inhibitors, Plain Adrenergics and Other Drugs for Obstructive Airway Diseases Gastroesophageal Reflux Disease, Peptic Ulcer Disease Proportion of TPS (%) Heart Failure, High Blood Pressure Asthma, Emphysema, Chronic Bronchitis Dihydropyridine Derivatives High Blood Pressure Anticholinesterases Alzheimer s Disease Tumor Necrosis Factor Alpha Inhibitors Rheumatoid Arthritis, Crohn s Disease (Anti-TNF Drugs) Anticholinergics Emphysema, Chronic Bronchitis Selective Serotonin Reuptake Inhibitors Depression, Anxiety, Panic Disorder Combined Top 10 1, Notes * The nine jurisdictions submitting claims data to the NPDUIS Database as of December 2013 are Prince Edward Island, Nova Scotia, New Brunswick, Ontario, Manitoba, Saskatchewan, Alberta, British Columbia and the First Nations and Inuit Health Branch. TPS: Total program spending. Source National Prescription Drug Utilization Information System Database, Canadian Institute for Health Information. iv. In 2012, seniors accounted for 61.5% of program spending in all provinces based on NHEX data and 59.1% of spending in the nine jurisdictions included in this study, based on NPDUIS Database data. 12

25 Only three drug classes statins, anti-tnf drugs and selective serotonin reuptake inhibitors (SSRIs) appeared in both the top 10 drug classes in terms of drug program spending for both seniors and non-seniors (Table 5). Among non-seniors, five of the top 10 drug classes were psychotropic drugs, used to treat a variety of mental health conditions. These classes accounted for 15.9% of drug program spending on non-seniors in Table 5: Top 10 Drug Classes by Total Program Spending on Non-Seniors, Selected Jurisdictions,* 2012 Drug Class Common Uses Tumor Necrosis Factor Alpha Inhibitors (Anti-TNF Drugs) Natural Opium Alkaloids Rheumatoid Arthritis, Crohn s Disease Management of Moderate to Severe Pain TPS ($ Millions) Proportion of TPS (%) Diazepines, Oxazepines, Thiazepines Schizophrenia, Bipolar Disorder and Oxepines Other Antipsychotics Schizophrenia, Bipolar Disorder Other Antidepressants Depression Selective Serotonin Reuptake Inhibitors Depression Interferons Multiple Sclerosis, Chronic Hepatitis C Antivirals for Treatment of HIV HIV Infections, Combinations Drugs Used in Opioid Dependence Drug Addiction, Pain Control HMG-CoA Reductase Inhibitors High Cholesterol Combined Top 10 1, Notes * The nine jurisdictions submitting claims data to the NPDUIS Database as of December 2013 are Prince Edward Island, Nova Scotia, New Brunswick, Ontario, Manitoba, Saskatchewan, Alberta, British Columbia and the First Nations and Inuit Health Branch. TPS: Total program spending. Source National Prescription Drug Utilization Information System Database, Canadian Institute for Health Information. How Is Public Drug Program Spending Distributed? The majority of public drug spending was for a relatively small number of high-cost individuals. In 2012, public drug programs paid $2,500 or more toward drug costs for 12.7% of beneficiaries. These beneficiaries accounted for 60.8% of public drug spending. Conversely, the programs paid less than $500 on drug costs for more than half (52.1%) of beneficiaries, accounting for only 6.2% of program spending (Table 6). 13

26 Table 6: Percentage of Paid Beneficiaries and Total Drug Program Spending, by Program Spending per Paid Beneficiary, 2012, Selected Jurisdictions* Program Spending Proportion of Paid Beneficiaries (%) Proportion of TPS (%) <$ $500 $1, $1,500 $2, $2,500 $4, $5,000 $9, $10, Notes * The nine jurisdictions submitting claims data to the NPDUIS Database as of December 2013 are Prince Edward Island, Nova Scotia, New Brunswick, Ontario, Manitoba, Saskatchewan, Alberta, British Columbia and the First Nations and Inuit Health Branch. TPS: Total program spending. Source National Prescription Drug Utilization Information System Database, Canadian Institute for Health Information. The distribution of cost in each jurisdiction is similar to the overall pattern (see Appendix H). The proportion of individuals for whom the drug program covered less than $500 in drug costs ranged from 71.1% for FNIHB to 36.3% in Nova Scotia. In contrast, the proportion of individuals for whom the drug program paid $5,000 or more toward drug costs is significantly smaller, ranging from 7.1% in Manitoba to 2.3% for FNIHB. Which Drugs Contributed to the Observed Trends in Public Drug Program Spending? Public drug program spending increased at an average rate of 6.3% per year among provinces for which NPDUIS Database data is available for both 2002 and v While drug program spending continued to increase, the rate of growth decreased substantially during the past five years, with an annual average rate of growth of 3.5% from 2007 to 2012 compared with 9.2% from 2002 to Between 2007 and 2012, anti-tnf drugs contributed to more than half (54.8%) of the growth in drug program spending and were the top contributor to growth in each jurisdiction for which data was available. vi Two of the top three drug classes that contributed most to the growth of public drug spending, anti-tnf drugs and antineovascularization agents, were newer classes of drugs known as biologic agents (Table 7). Antineovascularization agents exhibited the highest average annual growth rate in terms of public drug program spending between 2007 and 2012, at 129.0%, followed by anti-tnfs, growing at an average annual rate of 28.1%. Again, it should be noted that Alberta accounts for the majority of ranibizumab spending in this calculation. Therefore, the growth rate would likely have been even higher if spending from other jurisdictions was included. In most of the other provinces where ranibizumab spending is not captured, anti-tnf agents were the fastest-growing drug class in terms of spending. v. Data from five provinces is included: Nova Scotia, New Brunswick, Manitoba, Saskatchewan and Alberta. vi. Data from seven provinces in included: P.E.I., Nova Scotia, New Brunswick, Manitoba, Saskatchewan, Alberta and B.C. 14

27 Both antineovascularization and anti-tnf drugs are relatively expensive. Biologic agents are often more expensive than alternative medications (where they exist), and drug programs in the nine jurisdictions spent an average of $9,104 and $17,782 per paid beneficiary on antineovascularization agents and anti-tnfs, respectively, in Table 7: Top 10 Drug Classes by Contribution to Total Program Spending Growth, Average Annual Growth, Selected Jurisdictions,* 2007 to 2012 Average Annual Growth (%) Drug Class Common Use Contribution to TPS Growth (%) Tumor Necrosis Factor Alpha Rheumatoid Arthritis, Crohn s Disease Inhibitors (Anti-TNF Drugs) Antineovascularization Agents Age-Related Macular Degeneration Adrenergics and Other Drugs for Obstructive Airway Diseases Asthma, Emphysema, Chronic Bronchitis Other Antipsychotics Schizophrenia, Bipolar, Dementia, Affective Disorder Drugs Used in Opioid Dependence Drug Addiction, Pain Control Anticholinergics Emphysema, Chronic Bronchitis Natural Opium Alkaloids Management of Moderate to Severe Pain Anticholinesterases Alzheimer s Disease Other Antiepileptics Epilepsy, Pain Selective Serotonin Reuptake Inhibitors (SSRIs) Depression, Anxiety, Panic Disorder Notes * The seven jurisdictions submitting claims data to the NPDUIS Database as of December 2013 are Prince Edward Island, Nova Scotia, New Brunswick, Manitoba, Saskatchewan, Alberta and British Columbia. Ontario and First Nations and Inuit Health Branch data is not available prior to 2011; these jurisdictions are thus excluded from the results. TPS: Total program spending. Source National Prescription Drug Utilization Information System Database, Canadian Institute for Health Information. The increased spending on these relatively high-cost drug classes led to a shift in the distribution of drug program spending across individuals. Among the seven jurisdictions vii for which data is available for 2007 and 2012, the proportion of drug program spending on beneficiaries for whom the drug program paid $10,000 or more in drug spending increased from 14.5% in 2007 to 25.5% in 2012, while the proportion of beneficiaries they account for increased by less than 1 percentage point (Appendix H). Among these high-cost individuals, almost half (45.5%) had a claim for either anti-tnf or antineovascularization drugs in 2012, compared with about one-quarter (23.1%) in vii. Data from seven jurisdictions is included: P.E.I., Nova Scotia, New Brunswick, Manitoba, Saskatchewan, Alberta and B.C. 15

28 As previously mentioned, the rate of growth in drug spending has decreased substantially during the past five years. It is not surprising that similar trends were observed in eight of the top 10 drug classes in terms of drug spending in 2012 (Table 8). This was due in large part to patent expiries for commonly used chemicals after 2007, which occurred in all but one of these eight drug classes (opioids). Statins, for instance, had one of the highest proportions of total program spending (5.6%) in 2012; however, public drug program spending on this class declined by an average annual rate of 7.0% between 2007 and A decline in spending was also observed for three other top 10 drug classes: PPIs (commonly used to treat gastroesophageal reflux disease), ACE inhibitors (commonly used to lower blood pressure), and diazepines, oxazepines, thiazepines and oxepines (commonly used to treat schizophrenia and bipolar disorder). Table 8: Average Annual Growth in Total Program Spending for Top 10 Drug Classes by TPS, Selected Jurisdictions,* 2002 to 2012 Drug Class Tumor Necrosis Factor Alpha Inhibitors (Anti-TNF Drugs) HMG-CoA Reductase Inhibitors (Statins) Proton Pump Inhibitors Common Use Average Annual Growth in TPS 2002 to 2007 (%) Average Annual Growth in TPS 2007 to 2012 (%) Rheumatoid Arthritis, Crohn s Disease High Cholesterol Gastroesophageal Reflux Disease, Peptic Ulcer Disease Antineovascularization Agents Age-Related Macular Degeneration Adrenergics and Other Drugs for Asthma, Emphysema, Obstructive Airway Diseases Chronic Bronchitis Natural Opium Alkaloids Management of Moderate to Severe Pain Angiotensin-Converting Enzyme Heart Failure, High Blood Pressure (ACE) Inhibitors, Plain Selective Serotonin Depression Reuptake Inhibitors Diazepines, Oxazepines, Schizophrenia, Bipolar Disorder Thiazepines and Oxepines Other Antidepressants Depression Combined Top Notes * The five jurisdictions submitting claims data to the NPDUIS Database as of December 2013 are Nova Scotia, New Brunswick, Manitoba, Saskatchewan and Alberta. Ontario and First Nations and Inuit Health Branch data is not available prior to 2011, and Prince Edward Island and British Columbia data is not available prior to 2005; these jurisdictions are thus excluded from the results. TPS: Total program spending. Source National Prescription Drug Utilization Information System Database, Canadian Institute for Health Information. 16

29 In each of these four classes, patents on commonly used drugs expired, allowing for the entry of lower-priced generic versions. Looking at the share of generic drug spending for these four classes, all of them experienced a shift from brand to generic products during the study period (Figure 6). Between 2002 and 2012, the generic share of public program spending for statins increased from 15.5% to 74.5%; ACE inhibitors increased from 16.3% to 64.1%; and diazepines, oxazepines, thiazepines and oxephines from 0.4% to 82.4%. Between 2007 and 2012, PPIs increased from 27.1% to 79.9%. Figure 6: Distribution of Total Drug Program Spending on Selected Drug Classes, by Type of Drug, Selected Jurisdictions,* 2002 to 2012 Notes * The five jurisdictions submitting claims data to the NPDUIS Database as of March 2013 are Nova Scotia, New Brunswick, Manitoba, Saskatchewan and Alberta. Ontario and First Nations and Inuit Health Branch data is not available prior to 2011, and Prince Edward Island and British Columbia data is not available prior to 2005; these jurisdictions are thus excluded from the results. PPIs: Proton pump inhibitors. ACE: Angiotensin-converting enzyme. Source National Prescription Drug Utilization Information System Database, Canadian Institute for Health Information. 17

30 The impact of the entry of lower-cost generic products in these classes was further amplified with the implementation of generic pricing policies by public drug programs over the past five years. Generic drug prices are now regulated in most provinces, ranging from 18% to 35% of the price of brand name products. Most recently, a Council of the Federation initiative reduced the prices for six commonly used generic drugs viii including a statin, an ACE inhibitor and two PPIs to 18% of the brand name price. Each of these chemicals belonged to one of the top 10 drug classes in terms of drug program spending in In 2012, generic products accounted for 38.8% of public drug program spending (Figure 7). Although the share of generic spending varies by province, generic products increased as a proportion of drug program spending over the past decade in each of the jurisdictions for which data was available in each year (Table 9). The share of generic spending can be skewed by the typically higher prices of brand name products. Generics as a share of the total number of accepted claims (rather than as a share of spending) accounted for 72.4% in Figure 7: Percentage Share of Total Drug Program Spending and Number of Accepted Claims (Brand Name and Generic), Selected Jurisdictions,* 2012 Note * The nine jurisdictions submitting claims data to the NPDUIS Database as of December 2013 are Prince Edward Island, Nova Scotia, New Brunswick, Ontario, Manitoba, Saskatchewan, Alberta, British Columbia and the First Nations and Inuit Health Branch. Source National Prescription Drug Utilization Information System Database, Canadian Institute for Health Information. viii. The six generic drugs include atorvastatin, ramipril, venlafaxine, amlodipine, omeprazole and rabeprazole. 18

31 Table 9: Generic Drugs as a Percentage of Total Drug Program Spending and Total Number of Accepted Claims, Selected Provinces,* 2002 to 2012 Jurisdiction Percentage of TPS (%) Percentage of Claims (%) Percentage of TPS (%) Percentage of Claims (%) Percentage of TPS (%) Percentage of Claims (%) P.E.I. N/A N/A N.S N.B Ont. N/A N/A N/A N/A Man Sask Alta B.C. N/A N/A FNIHB N/A N/A N/A N/A Notes * The nine jurisdictions submitting claims data to the NPDUIS Database as of December 2013 are Prince Edward Island, Nova Scotia, New Brunswick, Ontario, Manitoba, Saskatchewan, Alberta, British Columbia and the First Nations and Inuit Health Branch. TPS: Total program spending. N/A: Data not available. Source National Prescription Drug Utilization Information System Database, Canadian Institute for Health Information. It should be noted that the share of spending on generic products does not necessarily reflect the extent of use of generic products in place of brand products, as generic alternatives are not available in all cases (most often when the brand name product is still under patent). For cases where only generic products were available, generics accounted for 65.5% of spending and 80.6% of claims in

32

33 Appendix A: Glossary of Terms Please note that some of the terms in this glossary may have alternate definitions. The stated definitions are meant only to reflect how these terms were used in the context of this report and are not necessarily the sole definitions of these terms. accepted claim: A claim where the drug program accepts at least a portion of the cost, either toward a deductible or for reimbursement. active beneficiary: An individual with at least one claim accepted by a public drug program, either for reimbursement or applied toward a deductible. In Manitoba and Saskatchewan, claimants are also individuals with accepted claims who are eligible for coverage under a provincial drug program but who have not submitted an application and, therefore, do not have a defined deductible. amount paid per paid beneficiary: The average amount paid by the plan/program per individual, for whom the public plan/program paid at least part of one claim. Anatomical Therapeutic Chemical (ATC) level: A classification system that divides drugs into different groups according to the organ or system on which they act and their chemical, pharmacological and therapeutic properties. average annual growth rate: The constant annual rate necessary for a value at the beginning of a period to grow to a value at the end of a period over the number of compounding years in the period. (See Appendix E for more detail.) broad therapeutic category: Subgroups of chemicals classified by the World Health Organization at the first level of the ATC classification system. At this level, groups are, in theory, regarded as groups of different chemicals that act on the same organ or system. claim: One or more transactions, with the final result indicating that a prescription had been filled and dispensed in exchange for payment. copayment: The portion of the claim cost that individuals must pay each time they make a claim. This may be a fixed amount or a percentage of the total claim cost. When calculated as a percentage of the total cost, it is also known as co-insurance. cost sharing: The amount of the total prescription cost accepted by the plan/program that is not paid by the plan/program (that is, the amount of the total prescription cost accepted that is paid out of pocket by the beneficiary or through another plan/program/insurer). cost-sharing mechanisms: The ways through which prescription costs can be shared between drug programs and their beneficiaries (for example, copayments, deductibles and premiums). deductible: The amount of total drug spending an individual must pay in a given year (or other defined time period) before any part of his or her drug costs will be paid by the drug program. A deductible may be a fixed amount or a percentage of income (income-based deductible). 21

34 drug class: Subgroups of chemicals classified by the World Health Organization at the fourth level of the ATC classification system. At this level, subgroups are, in theory, regarded as groups of different chemicals that work in the same way to treat similar medical conditions (for example, the chemical subgroup bisphosphonates includes chemicals such as etidronate, alendronate and risedronate). drug program: A program that provides coverage for drugs for a set population. Programs have defined rules for eligibility, payment and the drugs they cover. drug program formulary: A formal listing of the benefits eligible for reimbursement under a specific drug benefit plan/program and the conditions under which coverage is provided. For the purpose of the NPDUIS Database, a benefit means a drug, product, medical supply, equipment item or service covered under a drug benefit plan or program. drug program spending: The amount paid by the drug program toward an individual s prescription costs. Any portion of the prescription cost paid by the individual or a third-party private insurer is not captured in this amount, including the drug cost, professional fees paid to the pharmacy or markup charged by the pharmacy. (See Appendix E for more detail.) indication: Refers to the use of a drug for treating a particular disease. For example, gastroesophageal reflux disease is an indication for proton pump inhibitors. jurisdiction: The federal/provincial/territorial jurisdiction responsible for the drug program formulary and for financing the paid amount of accepted claims. paid beneficiary: An individual who has had, at least, part of at least one claim paid by a plan/program as a benefit. paid claim: A claim for which the drug program paid at least a portion of the cost. palliative: Individuals who have been diagnosed by a physician or nurse practitioner as being in the end stage of a terminal illness or disease, who are aware of their diagnosis and have made a voluntary informed decision related to resuscitation, and for whom the focus of care is palliation and not treatment aimed at a cure. premium: The amount an individual must pay to enrol in the drug program. public drug coverage: Drug coverage offered to individuals by the federal/provincial/ territorial jurisdictions. total drug program spending: See drug program spending. 22

Prescribed Drug Spending in Canada, 2013: A Focus on Public Drug Programs

Prescribed Drug Spending in Canada, 2013: A Focus on Public Drug Programs Prescribed Drug Spending in Canada, 2013: A Focus on Public Drug Programs Spending and Health Workforce Our Vision Better data. Better decisions. Healthier Canadians. Our Mandate To lead the development

More information

Drug Use Among Seniors on Public Drug Programs in Canada, 2002 to 2008

Drug Use Among Seniors on Public Drug Programs in Canada, 2002 to 2008 Drug Use Among Seniors on Public Drug Programs in Canada, 2002 to 2008 National Prescription Drug Utilization Information System Database Production of this report is made possible by financial contributions

More information

Drug Use Among Seniors on Public Drug Programs in Canada, 2012

Drug Use Among Seniors on Public Drug Programs in Canada, 2012 Drug Use Among Seniors on Public Drug Programs in Canada, 2012 Report May 2014 Types of Care Our Vision Better data. Better decisions. Healthier Canadians. Our Mandate To lead the development and maintenance

More information

Drivers of Prescription Drug Spending in Canada

Drivers of Prescription Drug Spending in Canada Drivers of Prescription Drug Spending in Canada Spending and Health Workforce Who We Are Established in 1994, CIHI is an independent, not-for-profit corporation that provides essential information on Canada

More information

4.0 Health Expenditure in the Provinces and Territories

4.0 Health Expenditure in the Provinces and Territories 4.0 Health Expenditure in the Provinces and Territories Health expenditure per capita varies among provinces/territories because of different age distributions. xii Population density and geography also

More information

Article from: The Actuary Magazine. October/November 2013 Volume 10, Issue 5

Article from: The Actuary Magazine. October/November 2013 Volume 10, Issue 5 Article from: The Actuary Magazine October/November 2013 Volume 10, Issue 5 the increase in drug costs for private plans is about 5.2 percent per year, while the annual growth for governmentsponsored drug

More information

Guide to Canadian benefits Legislation

Guide to Canadian benefits Legislation Guide to Canadian benefits Legislation 2014 PROVINCIAL ROADMAP PROVINCIAL ROADMAP to the Canadian Benefits Legislation Landscape BC-ALBERTA-SASK - 1 The federal government, ten provinces, and three territories

More information

Canadian Publicly Funded Prescription Drug Plans, Expenditures and an Overview of Patient Impacts

Canadian Publicly Funded Prescription Drug Plans, Expenditures and an Overview of Patient Impacts Canadian Publicly Funded Prescription Drug Plans, Expenditures and an Overview of Patient Impacts Prepared for Alberta Health Fiona M. Clement PhD; Lesley J.J. Soril MSc; Herbert Emery PhD; David J.T.

More information

April 19, 2009. Olaf Koester

April 19, 2009. Olaf Koester Utilization Management Agreements: A new policy direction April 19, 2009 Olaf Koester Director, Drug Management Policy Unit Manitoba Health and Healthy Living Presentation Outline Expenditure Trends Manitoba

More information

Occupational Therapists in Canada, 2010 National and Jurisdictional Highlights and Profiles

Occupational Therapists in Canada, 2010 National and Jurisdictional Highlights and Profiles Occupational Therapists in Canada, 2010 National and Jurisdictional Highlights and Profiles October 2011 Spending and Health Workforce Who We Are Established in 1994, CIHI is an independent, not-for-profit

More information

Pharmacist Workforce, 2012 Provincial/Territorial Highlights

Pharmacist Workforce, 2012 Provincial/Territorial Highlights pic pic Pharmacist Workforce, 2012 Provincial/Territorial Highlights Spending and Health Workforce Our Vision Better data. Better decisions. Healthier Canadians. Our Mandate To lead the development and

More information

5.0 Provincial and Territorial Government Health Expenditure by Age and Sex

5.0 Provincial and Territorial Government Health Expenditure by Age and Sex 5.0 Provincial and Territorial Government Health Expenditure by Age and Sex CIHI has been collecting actual utilization data since 1996 from national and provincial/territorial administrative databases

More information

Analytical Bulletin Certified and Non-Certified Specialists: Understanding the Numbers

Analytical Bulletin Certified and Non-Certified Specialists: Understanding the Numbers Analytical Bulletin Certified and Non-Certified Specialists: Understanding the Numbers CIHI Physician Databases 2004:2 Introduction Physician count information is available from a number of Canadian data

More information

The Regulation and Supply of Nurse Practitioners in Canada: Health Expenditure Estimates

The Regulation and Supply of Nurse Practitioners in Canada: Health Expenditure Estimates The Regulation and Supply of Nurse Practitioners in Canada: Preliminary Technical Provincial Appendix and Territorial Government Health Expenditure Estimates 1974 1975 to 2004 2005 The Regulation and

More information

Rx Atlas. The Canadian. Third Edition. The following pages are an excerpt from. December 2013

Rx Atlas. The Canadian. Third Edition. The following pages are an excerpt from. December 2013 The following pages are an excerpt from The Canadian Rx Atlas Third Edition December 2013 British Columbia Alberta Saskatchewan Manitoba Ontario Quebec New Brunswick Nova Scotia Newfoundland and Labrador

More information

Health Care Coverage and Costs in Retirement

Health Care Coverage and Costs in Retirement Health Care Coverage and Costs in Retirement Health care coverage and costs should be an important consideration in your retirement planning. You need to have an idea of what coverage you will need and

More information

Consistent Results Across Most of The Board

Consistent Results Across Most of The Board Canadian Health Care Trend Survey Results 2015 Consistent Results Across Most of The Board Our 2015 Health Care Trend Survey demonstrates that drug, health and dental cost trend factors have remained consistent

More information

Nurse Practitioners in Canada

Nurse Practitioners in Canada Nurse Practitioners in Canada Prepared for the Health Care Co-operative Federation of Canada Biju Mathai, BSc Policy and Research Intern Canadian Co-operative Association March 20, 2012 Nurse Practitioners

More information

The Burden of Out-of-Pocket Costs for Canadians with Diabetes

The Burden of Out-of-Pocket Costs for Canadians with Diabetes The Burden of Out-of-Pocket Costs for Canadians with Diabetes The Issue: Government coverage of diabetes medications, devices and supplies varies across jurisdictions, leaving some costs for these supports

More information

The Blueprint for Pharmacy and Pharmacy Technicians: History and Future

The Blueprint for Pharmacy and Pharmacy Technicians: History and Future The Blueprint for Pharmacy and Pharmacy Technicians: History and Future Presented by: Kristine Petrasko, BScPharm, CRE CPhA Board Member for Manitoba Created by: Conrad Amenta, Project Director Blueprint

More information

Can an administrative drug claims database be used to understand claimant drug utilization?

Can an administrative drug claims database be used to understand claimant drug utilization? Can an administrative drug claims database be used to understand claimant drug utilization? By Elaine McKenzie, BSP, MBA, Consultant, TELUS Health Analytics Elaine McKenzie is a consultant who works with

More information

Response to the New Brunswick Government Consultation on a Prescription Drug Plan for Uninsured New Brunswickers

Response to the New Brunswick Government Consultation on a Prescription Drug Plan for Uninsured New Brunswickers Response to the New Brunswick Government Consultation on a Prescription Drug Plan for Uninsured New Brunswickers Brief submitted by The New Brunswick Nurses Union April 2012 Background The New Brunswick

More information

Organization of the health care system and the recent/evolving human resource agenda in Canada

Organization of the health care system and the recent/evolving human resource agenda in Canada Organization of the health care system and the recent/evolving human resource agenda in Canada 1. Organization - the structural provision of health care. Canada has a predominantly publicly financed health

More information

Access to Prescription Drugs in New Brunswick

Access to Prescription Drugs in New Brunswick Access to Prescription Drugs in New Brunswick Discussion Paper Department of Health June 2015 Department of Health Published by: Department of Health Government of New Brunswick P. O. Box 5100 Fredericton,

More information

Catastrophic Drug Coverage for New Brunswick. A proposal by the Multiple Sclerosis Society of Canada, Atlantic Division

Catastrophic Drug Coverage for New Brunswick. A proposal by the Multiple Sclerosis Society of Canada, Atlantic Division Catastrophic Drug Coverage for New Brunswick A proposal by the Multiple Sclerosis Society of Canada, Atlantic Division July 2010 Proposal for a Catastrophic Drug Program in New Brunswick i Executive Summary

More information

Spending on Prescriptions in 2011

Spending on Prescriptions in 2011 Issue Brief #4 September 2012 Spending on Prescriptions in 2011 Findings from HCCI s Health Care Cost and Utilization Report: 2011 This issue brief highlights and expands on findings on prescriptions from

More information

PharmaCare is BC s public drug insurance program that assists BC residents in paying for eligible prescription drugs and designated medical supplies.

PharmaCare is BC s public drug insurance program that assists BC residents in paying for eligible prescription drugs and designated medical supplies. PHARMANET AND PHARMACARE DATA DICTIONARY Date Range: September 1, 1995 to present date, data is provided by calendar year Data Source: BC Ministry of Health Description The PharmaNet system is an online,

More information

Atlantic Provinces 71 COMMUNITIES

Atlantic Provinces 71 COMMUNITIES NATIONAL STUDY OF AUTOMOBILE INSURANCE RATES Third Release Atlantic Provinces 71 COMMUNITIES vs. British Columbia, Alberta Saskatchewan, Manitoba & Ontario 3,985,162 Auto Insurance Rates Compared October

More information

Wait Times for Priority Procedures in Canada, 2014

Wait Times for Priority Procedures in Canada, 2014 March 2014 Wait Times for Priority Procedures in Canada, 2014 Types of Care Canadians have indicated that waiting too long for care is the largest barrier to accessing health services. 1 As a result, policy-makers

More information

The Regulation and Supply of Nurse Practitioners in Canada. Preliminary Provincial and Territorial Government. Health Expenditure Estimates

The Regulation and Supply of Nurse Practitioners in Canada. Preliminary Provincial and Territorial Government. Health Expenditure Estimates The Regulation and Supply of Nurse Practitioners in Canada Preliminary Provincial and Territorial Government Health Expenditure Estimates 1974 1975 to 2004 2005 All rights reserved. Contents of this publication

More information

Public Health Care Insurance in Canada:

Public Health Care Insurance in Canada: A Comparison of Provincial and Territorial Programs Provisions current to October 1 2010 A Comparison of Provincial and Territorial Programs i CANADA Supplementary group employee health benefit programs,

More information

Regulated Nurses, 2013

Regulated Nurses, 2013 Report July 2014 Spending and Health Workforce Our Vision Better data. Better decisions. Healthier Canadians. Our Mandate To lead the development and maintenance of comprehensive and integrated health

More information

Spending on Postsecondary. of Education, Fact Sheet. Education Indicators in Canada. June 2011

Spending on Postsecondary. of Education, Fact Sheet. Education Indicators in Canada. June 2011 Catalogue no. 81-599-X Issue no. 007 ISSN: 1709-8653 ISBN: 978-1-100-18860-7 Education Indicators in Canada Spending on Postsecondary Education June 2011 Tourism and the Centre for Education Statistics

More information

Group insurance. Drug insurance Integrated plan management solutions

Group insurance. Drug insurance Integrated plan management solutions Group insurance Drug insurance Integrated plan management solutions Our vision We are a Canadian leader in group insurance recognized for our optimal approach to health management, our close client relationships

More information

CHAPTER 4. Eye Care in the Private Sector: Innovation at the Service of Patients

CHAPTER 4. Eye Care in the Private Sector: Innovation at the Service of Patients CHAPTER 4 Eye Care in the Private Sector: Innovation at the Service of Patients In Canada, it is professionals working essentially in private practices who provide patients with the eye and vision care

More information

Report of the Advisory Committee on Health Benefits: An Insurance Plan for Prescription Drugs for Uninsured New Brunswickers

Report of the Advisory Committee on Health Benefits: An Insurance Plan for Prescription Drugs for Uninsured New Brunswickers Report of the Advisory Committee on Health Benefits: An Insurance Plan for Prescription Drugs for Uninsured New Brunswickers Prepared for ESIC Board of Directors Final Report December 2012 Final Report

More information

Your Retiree Health Care Travel Guide

Your Retiree Health Care Travel Guide SPECIAL EDITION for Individuals Not Yet Eligible for Medicare Your Retiree Health Care Travel Guide 2010 Enrollment for BorgWarner Pre-Medicare Health Care Coverage Welcome to 2010 Pre-Medicare enrollment!

More information

Canadian Provincial and Territorial Early Hearing Detection and Intervention. (EHDI) Programs: PROGRESS REPORT

Canadian Provincial and Territorial Early Hearing Detection and Intervention. (EHDI) Programs: PROGRESS REPORT Canadian Provincial and Territorial Early Hearing Detection and Intervention (EHDI) Programs: PROGRESS REPORT www.sac-oac.ca www.canadianaudiology.ca 1 EHDI PROGRESS REPORT This progress report represents

More information

Where you live matters: Canadian views on health care quality

Where you live matters: Canadian views on health care quality JANUARY 14 Canadian Health Care Matters Bulletin 8 Where you live matters: Canadian views on health care quality Results from the 13 Commonwealth Fund International Health Policy Survey of the General

More information

NCLEX-RN 2015: Canadian Results. Published by the Canadian Council of Registered Nurse Regulators (CCRNR)

NCLEX-RN 2015: Canadian Results. Published by the Canadian Council of Registered Nurse Regulators (CCRNR) NCLEX-RN 2015: Canadian Results Published by the Canadian Council of Registered Nurse Regulators (CCRNR) March 31, 2016 Contents Message from the president 3 Background on the NCLEX-RN 4 The role of Canada

More information

WESTCHESTER COMMUNITY COLLEGE Valhalla, NY 10595. COURSE TITLE: Pharmacology (for Nursing and Health Fields) COURSE NUMBER: Biology 202

WESTCHESTER COMMUNITY COLLEGE Valhalla, NY 10595. COURSE TITLE: Pharmacology (for Nursing and Health Fields) COURSE NUMBER: Biology 202 WESTCHESTER COMMUNITY COLLEGE Valhalla, NY 10595 SYLLABUS FORM COURSE TITLE: Pharmacology (for Nursing and Health Fields) COURSE NUMBER: Biology 202 1. NAME OF COURSE: Pharmacology (for Nursing and Health

More information

Tobacco Use in Canada: Patterns and Trends. 2012 Edition

Tobacco Use in Canada: Patterns and Trends. 2012 Edition Tobacco Use in Canada: Patterns and Trends 212 Edition Tobacco Use in Canada: Patterns and Trends 212 Edition This report was prepared by Jessica Reid, MSc, and David Hammond, PhD. Data analysis was completed

More information

Alberta Government Health Insurance Plan offers Limited Coverage.

Alberta Government Health Insurance Plan offers Limited Coverage. Alberta Government Health Insurance Plan offers Limited Coverage. Alberta government provides supplementary health coverage via Blue Cross to individuals in low-income; assured-income or other programs

More information

Addressing Dental Hygiene Labour Shortages in Rural and Remote Areas. A submission to the

Addressing Dental Hygiene Labour Shortages in Rural and Remote Areas. A submission to the Addressing Dental Hygiene Labour Shortages in Rural and Remote Areas A submission to the House of Commons Standing Committee on Human Resources, Skills and Social Development and the Status of Persons

More information

APPLICATION FOR PROFESSIONAL AND COMMERCIAL GENERAL LIABILITY INSURANCE FOR MEMBERS OF THE CANADIAN ASSOCIATION OF OPTOMETRISTS

APPLICATION FOR PROFESSIONAL AND COMMERCIAL GENERAL LIABILITY INSURANCE FOR MEMBERS OF THE CANADIAN ASSOCIATION OF OPTOMETRISTS Canadian Association of Optometrists APPLICATION FOR PROFESSIONAL AND COMMERCIAL GENERAL LIABILITY INSURANCE FOR MEMBERS OF THE CANADIAN ASSOCIATION OF OPTOMETRISTS Name of Applicant: Business/Corporation

More information

DRUG COVERAGE for low-income families

DRUG COVERAGE for low-income families April 2015 DRUG COVERAGE for low-income families The Canadian reality and lessons from Switzerland and the Netherlands, by Nadeem Esmail and Bacchus Barua. Contents Foreword Dr. Brett Belchetz / i Executive

More information

Saskatchewan Small Business Profile 2012

Saskatchewan Small Business Profile 2012 Saskatchewan Small Business Profile 2012 October 2013 Economic and Competitive Analysis Branch www.economy.gov.sk.ca Table of Contents INTRODUCTION... 1 KEY FACTS... 3 1. SMALL BUSINESS SECTOR... 4 2.

More information

Regulated Nurses, 2012 Summary Report

Regulated Nurses, 2012 Summary Report Spending and Health Workforce Our Vision Better data. Better decisions. Healthier Canadians. Our Mandate To lead the development and maintenance of comprehensive and integrated health information that

More information

Princeton University Prescription Drug Plan Summary Plan Description

Princeton University Prescription Drug Plan Summary Plan Description Princeton University Prescription Drug Plan Summary Plan Description Princeton University Prescription Drug Plan Summary Plan Description January 2015 Contents Introduction... 1 How the Plan Works... 2

More information

BRM Programs What to Expect for the 2013 Program Year

BRM Programs What to Expect for the 2013 Program Year Growing Forward 2 is a five-year policy framework for Canada s agriculture and agri-food sector and the basis for the delivery of federal-provincial-territorial programs. Growing Forward 2 includes ongoing

More information

Regulated Nurses: Canadian Trends, 2007 to 2011

Regulated Nurses: Canadian Trends, 2007 to 2011 Spending and Health Workforce Our Vision Better data. Better decisions. Healthier Canadians. Our Mandate To lead the development and maintenance of comprehensive and integrated health information that

More information

University tuition fees, 2014/2015 Released at 8:30 a.m. Eastern time in The Daily, Thursday, September 11, 2014

University tuition fees, 2014/2015 Released at 8:30 a.m. Eastern time in The Daily, Thursday, September 11, 2014 University tuition fees, 2014/2015 Released at 8:30 a.m. Eastern time in The Daily, Thursday, September 11, 2014 Canadian full-time students in undergraduate programs paid 3.3% more on average in tuition

More information

Nova Scotia Pharmacare Programs

Nova Scotia Pharmacare Programs Nova Scotia Pharmacare Programs The Nova Scotia Family Pharmacare Program Effective December 2012 The information in this booklet is subject to change and does not replace the Health Services and Insurance

More information

Anatomical Therapeutic Chemical (ATC) classification and the Defined Daily Dose (DDD): principles for classifying and quantifying drug use

Anatomical Therapeutic Chemical (ATC) classification and the Defined Daily Dose (DDD): principles for classifying and quantifying drug use Anatomical Therapeutic Chemical (ATC) classification and the Defined Daily Dose (DDD): principles for classifying and quantifying drug use DRAFT Yong Chen Merck, Whitehouse Station, NJ USA Disclosure Author

More information

Chronic Disease and Nursing:

Chronic Disease and Nursing: Chronic Disease and Nursing: A Summary of the Issues What s the issue? Chronic diseases are now the major global disease problem facing the world and a key barrier to development, to alleviating poverty,

More information

Authors: Julie Byles Deborah Loxton Janneke Berecki Xenia Dolja-Gore Richard Gibson Richard Hockey Ian Robinson Lynne Parkinson Lyn Adamson Jayne

Authors: Julie Byles Deborah Loxton Janneke Berecki Xenia Dolja-Gore Richard Gibson Richard Hockey Ian Robinson Lynne Parkinson Lyn Adamson Jayne Use and costs of and other health care resources: Findings from the Australian Longitudinal Study on Women s Health Authors: Julie Byles Deborah Loxton Janneke Berecki Xenia Dolja-Gore Richard Gibson Richard

More information

Prescription Drugs. Inside this Brief. Background Brief on

Prescription Drugs. Inside this Brief. Background Brief on Background Brief on Prescription Drugs Prepared by: Rick Berkobien Inside this Brief November 2006 Spending for Prescription Drugs Medicare and Prescription Drugs Drug Costs in Other Countries and the

More information

CLOSING THE COVERAGE GAP. Pan-Canadian Pharmacare

CLOSING THE COVERAGE GAP. Pan-Canadian Pharmacare CLOSING THE COVERAGE GAP Pan-Canadian Pharmacare Prescription drug coverage for all Canadians While the vast majority of Canadians have access to prescription drugs, some Canadians can t afford their medications.

More information

Canadian Nurse Practitioner Core Competency Framework

Canadian Nurse Practitioner Core Competency Framework Canadian Nurse Practitioner Core Competency Framework January 2005 Table of Contents Preface... 1 Acknowledgments... 2 Introduction... 3 Assumptions... 4 Competencies... 5 I. Health Assessment and Diagnosis...

More information

Coventry Health Care of Georgia, Inc. Coventry Health and Life Insurance Company

Coventry Health Care of Georgia, Inc. Coventry Health and Life Insurance Company Coventry Health Care of Georgia, Inc. Coventry Health and Life Insurance Company PRESCRIPTION DRUG RIDER This Prescription Drug Rider is an attachment to the Coventry Health Care of Georgia, Inc. ( Health

More information

PROVINCIAL/TERRITORIAL COMPASSIONATE LEAVE LEGISLATION Provinces/Territories with Compassionate Care Leave Legislation

PROVINCIAL/TERRITORIAL COMPASSIONATE LEAVE LEGISLATION Provinces/Territories with Compassionate Care Leave Legislation PROVINCIAL/TERRITORIAL COMPASSIONATE LEAVE LEGISLATION Provinces/Territories with Compassionate Care Leave Legislation Almost all of the provinces and territories either had existing labour legislation

More information

How To Improve The Health Care System In Ohio

How To Improve The Health Care System In Ohio MINISTRY OF HEALTH AND LONG-TERM CARE 3.09 Drug Programs Activity BACKGROUND Ontario s drug programs are administered by the Drug Programs Branch (Branch) of the Ministry of Health and Long-Term Care.

More information

Specialty Drug Care: Case management services in Quebec

Specialty Drug Care: Case management services in Quebec Specialty Drug Care: Case management services in Quebec QUEBEC SUPPORTING HEALTHIER OUTCOMES Your health benefit plan is designed to provide you and your family with financial protection for a variety

More information

Tobacco Use in Canada: Patterns and Trends

Tobacco Use in Canada: Patterns and Trends Tobacco Use in Canada: Patterns and Trends 21 EDITION University of Waterloo Waterloo, Ontario www.tobaccoreport.ca Tobacco Use in Canada: Patterns and Trends 21 Edition This report was prepared by Jessica

More information

Prescription drug costs continue to rise at

Prescription drug costs continue to rise at Prescription Drugs Developing an Effective Generic Prescription Drug Program by John D. Jones Pharmacy benefit managers (PBMs) use a variety of pricing strategies. When employers have a thorough knowledge

More information

Engineers Canada 2012 Membership Survey

Engineers Canada 2012 Membership Survey Engineers Canada 2012 Membership Survey June 3, 2013 Contents List of Tables... i List of Figures... ii Descriptions of Membership Categories... iii 1 Introduction... 1 2 Membership Composition... 1 2.1

More information

taxation Current to June 20, 2013 What s Inside www.bdo.ca

taxation Current to June 20, 2013 What s Inside www.bdo.ca www.bdo.ca taxation Tax Facts 2013 Current to June 20, 2013 Tax Facts 2013 provides you with a summary of 2013 personal income tax rates and amounts, as well as corporate tax rates (as at July 1, 2013),

More information

Potential Savings from Generic Drugs in Upstate New York

Potential Savings from Generic Drugs in Upstate New York T H E F A C T S A B O U T Potential Savings from Generic Drugs in Upstate New York $880 Million in Potential Savings for Upstate New York Counties Finger Lakes Region $141 million Western New York Region

More information

White Paper. Medicare Part D Improves the Economic Well-Being of Low Income Seniors

White Paper. Medicare Part D Improves the Economic Well-Being of Low Income Seniors White Paper Medicare Part D Improves the Economic Well-Being of Low Income Seniors Kathleen Foley, PhD Barbara H. Johnson, MA February 2012 Table of Contents Executive Summary....................... 1

More information

2010 National Physician Survey :

2010 National Physician Survey : 2010 National Physician Survey : Family Physician Usage of Electronic Medical Records Inese Grava-Gubins, Artem Safarov, Jonas Eriksson College of Family Physicians of Canada CAHSPR, Montreal, May 2012

More information

In the balance: A Renewed Vision for the Common Drug Review

In the balance: A Renewed Vision for the Common Drug Review In the balance: A Renewed Vision for the Common Drug Review April 2012 Executive Summary Purpose of This Report: A New Vision Equal and timely access to medications as clinically appropriate is an important

More information

Report of the CMEC Quality Assurance Subcommittee

Report of the CMEC Quality Assurance Subcommittee Report of the CMEC Quality Assurance Subcommittee 2007 2007 CMEC Jurisdictional Update on Activities Related to Quality Assurance Introduction In February 2007, ministers responsible for advanced education

More information

H - Pharmacy Technicians

H - Pharmacy Technicians / Hospital Pharmacy in Canada Report Chapter H Pharmacy Technicians H - Pharmacy Technicians Kyle MacNair, Chuck Wilgosh Introduction The landscape of pharmacy technician practice in Canada is rapidly

More information

Occupational Injuries and Diseases in Canada, 1996 2008

Occupational Injuries and Diseases in Canada, 1996 2008 Fair, Safe and Productive Workplaces Labour Occupational Injuries and Diseases in Canada, 1996 2008 Injury Rates and Cost to the Economy Jaclyn Gilks and Ron Logan Research and Analysis, Occupational Health

More information

Workforce Trends of Licensed Practical Nurses in Canada, 2005

Workforce Trends of Licensed Practical Nurses in Canada, 2005 2005 Workforce Trends of Licensed Practical Nurses in Canada, 2005 L i c e n s e d P r a c t i c a l N u r s e s D a t a b a s e All rights reserved. No part of this publication may be reproduced or transmitted

More information

National Health Expenditure Trends, 1975 to 2012

National Health Expenditure Trends, 1975 to 2012 National Health Expenditure Trends, 1975 to 2012 Spending and Health Workforce Our Vision Better data. Better decisions. Healthier Canadians. Our Mandate To lead the development and maintenance of comprehensive

More information

Internet Connectivity Among Aboriginal Communities in Canada

Internet Connectivity Among Aboriginal Communities in Canada Internet Connectivity Among Aboriginal Communities in Canada Since its inception the Internet has been the fastest growing and most convenient means to access timely information on just about everything.

More information

Introduction. Plan sponsors include employers, unions, trust funds, associations and government agencies, and are also referred to as payors.

Introduction. Plan sponsors include employers, unions, trust funds, associations and government agencies, and are also referred to as payors. Maintaining the Affordability of the Prescription Drug Benefit: How Managed Care Organizations Secure Price Concessions from Pharmaceutical Manufacturers Introduction The purpose of this paper is to explain

More information

Fraser Alert. Canadians Celebrate Tax Freedom Day on June 6. June 2009. Main Conclusions. Market solutions to public policy problems

Fraser Alert. Canadians Celebrate Tax Freedom Day on June 6. June 2009. Main Conclusions. Market solutions to public policy problems Fraser Alert Market solutions to public policy problems June 2009 Canadians Celebrate Tax Freedom Day on June 6 Main Conclusions On Tax Freedom Day, the average Canadian family has earned enough money

More information

MEDICARE PART D THE BASICS

MEDICARE PART D THE BASICS THE BASICS Participation is voluntary. The income level and assets of beneficiaries determine the level of prescription assistance they will receive. Beneficiaries with incomes over 150% of the Federal

More information

Public Health Care - Drug Spending in Ontario, Canada

Public Health Care - Drug Spending in Ontario, Canada daleorr@economicinsight.ca June 21 Is Controlling Spending on Drugs the Key to Controlling the Health Care Budget? It is well known that spending by governments on health care has far outpaced growth in

More information

Domestic and International Medical Device Reimbursement

Domestic and International Medical Device Reimbursement Diverse Intelligence Solutions Growth Fuel New Thinking & Innovation Domestic and International Medical Device Reimbursement Deborah Schenberger, Ph.D. OMTEC, 2009 Overview Challenges of reimbursement

More information

Health Care Cost Drivers: The Facts.

Health Care Cost Drivers: The Facts. Health Care Cost Drivers: The Facts. Spending and Workforce Who We Are Established in 1994, CIHI is an independent, not-for-profit corporation that provides essential information on Canada s health system

More information

5. 16. Health Law in Canada. Constitutional Division of Power

5. 16. Health Law in Canada. Constitutional Division of Power Health Law in Canada Health care in Canada is a complex subject, some health care services are public, some are private and there are a number of different entities involved in regulating and providing

More information

CANCER DRUG ACCESS FOR CANADIANS

CANCER DRUG ACCESS FOR CANADIANS CANCER DRUG ACCESS FOR CANADIANS SEPTEMBER 2009 Cancer Drug Access for Canadians i Executive Summary Access to cancer drugs defined as the ability to obtain recommended cancer drug treatments in a timely

More information

Health Care Cost Drivers: Physician Expenditure Technical Report

Health Care Cost Drivers: Physician Expenditure Technical Report pic pic Health Care Cost Drivers: Physician Expenditure Technical Report Spending and Health Workforce Our Vision Better data. Better decisions. Healthier Canadians. Our Mandate To lead the development

More information

Saskatchewan Small Business Profile 2015

Saskatchewan Small Business Profile 2015 Saskatchewan Small Business Profile 2015 October 2015 Ministry of the Economy Performance and Strategic Initiatives Division economy.gov.sk.ca Table of Contents INTRODUCTION... 1 KEY FACTS... 3 1. SMALL

More information

Experiencing Integrated Care

Experiencing Integrated Care International Comparisons Experiencing Integrated Care Ontarians views of health care coordination and communication Results from the 2014 Commonwealth Fund International Health Policy Survey of Older

More information

A Year in Review: CIHI s 2013 2014 Annual Privacy Report

A Year in Review: CIHI s 2013 2014 Annual Privacy Report A Year in Review: CIHI s 2013 2014 Annual Privacy Report Our Vision Better data. Better decisions. Healthier Canadians. Our Mandate To lead the development and maintenance of comprehensive and integrated

More information

2015 Travelers Prescription Drug Plan Blue Cross Blue Shield Plan and United Healthcare Choice Plus Plan

2015 Travelers Prescription Drug Plan Blue Cross Blue Shield Plan and United Healthcare Choice Plus Plan 2015 Travelers Prescription Drug Plan Blue Cross Blue Shield Plan and United Healthcare Choice Plus Plan Plan Details, Programs, and Policies Table of Contents Click on the links below to be taken to that

More information

Canadian Health Insurance. The Medical Expense Tax Credit. Life s brighter under the sun. June 2012. health plans

Canadian Health Insurance. The Medical Expense Tax Credit. Life s brighter under the sun. June 2012. health plans Canadian Health Insurance tax Guide June 2012 Life s brighter under the sun Sun Life Assurance Company of Canada, 2012. Individuals may not deduct hospital and medical expenses from their income, but they

More information

The 2002 Report Card

The 2002 Report Card Background This info sheet summarizes the main findings of a November 2002 report by the Canadian HIV/AIDS Legal Network, entitled Action on HIV/AIDS in Prisons: Too Little, Too Late A Report Card. The

More information

Understanding specialty drugs

Understanding specialty drugs Group Benefits Understanding specialty drugs What your pharmaceutical benefits plan may look like over the next decade Between 2011 and 2014, the percentage of total drug spend represented by specialty

More information

Additional Tables, Youth Smoking Survey 2008-09

Additional Tables, Youth Smoking Survey 2008-09 Additional Tables, Youth Smoking Survey 2008-09 Table 1. cigar use in last 30 days, cigarillo/little cigar/cigar use in last 30 days, cigarette use in the last 30 days, self defining as a smoker, Canada,

More information

An introduction to the Pharmaceutical Benefits Scheme

An introduction to the Pharmaceutical Benefits Scheme An introduction to the Pharmaceutical Benefits Scheme Introduction The use of medicines is the most common health intervention to combat illness and disease and promote good health and wellness. Of the

More information

Seniors and the Health Care System: What Is the Impact of Multiple Chronic Conditions?

Seniors and the Health Care System: What Is the Impact of Multiple Chronic Conditions? January 2011 Seniors and the Health Care System: What Is the Impact of Multiple Chronic Conditions? Introduction Concern about chronic condition care is growing as the prevalence of chronic conditions

More information

PRESCRIPTION MEDICINES: COSTS IN CONTEXT

PRESCRIPTION MEDICINES: COSTS IN CONTEXT PRESCRIPTION MEDICINES: COSTS IN CONTEXT 2015 Since 2000, biopharmaceutical companies have brought MORE THAN 500 NEW TREATMENTS AND CURES to U.S. patients In the last 100 years, medicines have helped raise

More information

TRAVEL INSURANCE COVERAGE

TRAVEL INSURANCE COVERAGE TRAVEL INSURANCE COVERAGE Information compiled by the Canadian Hemophilia Society during the summer of 2009 TRAVEL INSURANCE COVERAGE TABLE OF CONTENTS INTRODUCTION. 3 TWO EXAMPLES OF TRAVEL INSURANCE

More information